在Immuneering Corp的临床试验数据中，仅有贫血和中性粒细胞减少两种不良事件的发生率达到或超过了10%的门槛，且严重程度均为3级及以上。具体而言，贫血的发生率为16%，而中性粒细胞减少的发生率略高，为18%。这两项数据凸显了该治疗方案在患者耐受性方面的关键特征，为评估其安全性提供了重要依据。
在Immuneering Corp的临床试验数据中，仅有贫血和中性粒细胞减少两种不良事件的发生率达到或超过了10%的门槛，且严重程度均为3级及以上。具体而言，贫血的发生率为16%，而中性粒细胞减少的发生率略高，为18%。这两项数据凸显了该治疗方案在患者耐受性方面的关键特征，为评估其安全性提供了重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.